AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biotechnology firm creating novel options for individuals affected by cannabinoid overdose and substance habit, in the present day introduced the pricing of its preliminary public providing of 3,000,000 shares of frequent inventory at a public providing worth of $7.00 per share. The gross proceeds from the providing to the Company, earlier than deducting underwriting reductions and commissions and different providing bills payable by the Company, are anticipated to be roughly $21.zero million. In addition, the Company has granted the underwriter a 30-day choice to buy from the Company as much as an extra 450,000 shares of frequent inventory to cowl over-allotments, if any, on the preliminary public providing worth, much less underwriting reductions and commissions.
The Company’s frequent inventory is predicted to start buying and selling on The Nasdaq Capital Market on May 7, 2021 below the ticker image “ANEB.” The providing is predicted to shut on May 11, 2021, topic to customary closing circumstances.
The Benchmark Company, LLC is appearing as sole Book Running Manager for the providing.
A registration assertion on Form S-1 (File No. 333-254979) regarding the shares was filed with the U.S. Securities and Exchange Commission (the “SEC”) and have become efficient on May 6, 2021. The providing is being made solely by means of a prospectus. Copies of the ultimate prospectus, when accessible, could also be obtained by contacting The Benchmark Company, LLC, Attn: Prospectus Department, 150 E. 58th Street, 17th ground, New York, New York 10155 or by calling (212) 312-6700 or by emailing firstname.lastname@example.org.
This press launch shall not represent a suggestion to promote or a solicitation of a suggestion to purchase, nor shall there be any sale of these securities in any state or jurisdiction by which such supply, solicitation or sale could be illegal previous to registration or qualification below the securities legal guidelines of any such state or jurisdiction.
About Anebulo Pharmaceuticals, Inc.
Anebulo is a clinical-stage biotechnology firm creating novel options for individuals affected by cannabinoid overdose and substance habit. Its lead product candidate, ANEB-001, is meant to reverse the adverse results of cannabinoid overdose inside one hour of administration. Clinical trials accomplished to this point have proven that ANEB-001 is quickly absorbed, nicely tolerated and results in weight reduction, an impact that’s according to central cannabinoid receptor kind 1 antagonism.